Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)Jacques Bernier, Jean Louis Lefèbvre, Jay S. Cooper et al.|Head & Neck|2005Cited by 1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02Lester J. Peters, Danny Rischin, Brian O’Sullivan et al.|Journal of Clinical Oncology|2010Cited by 806
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and NeckJosé Baselga, A. Eckardt, José Trigo et al.|Journal of Clinical Oncology|2005Cited by 491
Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Liz Kenny, Lester J. Peters et al.|Journal of Clinical Oncology|2010Cited by 372